According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “
ACER has been the topic of a number of other research reports. Raymond James assumed coverage on shares of Acer Therapeutics in a report on Friday, February 15th. They issued an “outperform” rating and a $40.00 price objective on the stock. HC Wainwright set a $55.00 price objective on shares of Acer Therapeutics and gave the stock a “buy” rating in a report on Wednesday, April 17th. ValuEngine cut shares of Acer Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, April 19th. Finally, BidaskClub upgraded shares of Acer Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 13th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Acer Therapeutics currently has an average rating of “Buy” and an average price target of $42.50.
Acer Therapeutics (NASDAQ:ACER) last announced its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.04. On average, equities analysts anticipate that Acer Therapeutics will post -3.08 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in ACER. BlackRock Inc. grew its holdings in shares of Acer Therapeutics by 36.0% during the third quarter. BlackRock Inc. now owns 10,591 shares of the biopharmaceutical company’s stock valued at $327,000 after buying an additional 2,805 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Acer Therapeutics during the third quarter valued at approximately $346,000. Vanguard Group Inc. grew its holdings in shares of Acer Therapeutics by 1,898.5% during the third quarter. Vanguard Group Inc. now owns 244,033 shares of the biopharmaceutical company’s stock valued at $7,526,000 after buying an additional 231,822 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of Acer Therapeutics by 1,898.5% during the third quarter. Vanguard Group Inc now owns 244,033 shares of the biopharmaceutical company’s stock valued at $7,526,000 after buying an additional 231,822 shares during the last quarter. Finally, Bank of Montreal Can grew its holdings in shares of Acer Therapeutics by 100.0% during the fourth quarter. Bank of Montreal Can now owns 3,210 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 1,605 shares during the last quarter. Institutional investors and hedge funds own 30.78% of the company’s stock.
About Acer Therapeutics
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Featured Article: Why are analyst ratings important in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.